Investment Thesis
Pre-revenue pharmaceutical company burning $1.2M in operating cash flow quarterly with $3.0M net losses and no visible path to commercialization; while the $10.3M cash position provides 8-9 quarters of runway, the absence of revenue combined with high cash burn in a regulated biotech environment presents significant fundamental risk.
Strengths
- Strong absolute cash position of $10.3M representing 82% of total assets
- Zero long-term debt with Debt/Equity ratio of 0.00x eliminates solvency risk
- Adequate liquidity with Current Ratio of 1.79x and no forced asset sales needed
Risks
- Pre-revenue company with no revenue generation in latest period
- Negative quarterly operating cash flow of -$1.2M with limited runway of 8-9 quarters
- Net losses of -$3.0M per period with negative ROE of -44.3% and ROA of -23.6%
- Pharmaceutical sector development and regulatory approval risk with unproven commercialization capability
- No insider trading activity suggests lack of management conviction
Key Metrics to Watch
- Time to regulatory approval and product commercialization
- Quarterly cash burn rate and cash runway depletion
- Operating cash flow trajectory toward breakeven
- Clinical trial progress and pipeline advancement milestones
Financial Metrics
Revenue
N/A
Net Income
-3.0M
EPS (Diluted)
$-4.00
Free Cash Flow
-1.2M
Total Assets
12.5M
Cash
10.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-44.3%
ROA
-23.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.79x
Quick Ratio
1.79x
Debt/Equity
0.00x
Debt/Assets
46.7%
Interest Coverage
-26.89x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T07:55:58.675961 |
Data as of: 2026-03-31 |
Powered by Claude AI